Asian Pacific Journal of Cancer Prevention

  • 제13권9호
  • /
  • Pages.4757-4761
  • /
  • 2012
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Impact of Low Versus Conventional Doses of Chemotherapy During Transcatheter Arterial Chemo-embolization on Serum Fibrosis Indicators and Survival of Liver Cancer Patients

  • Kong, Wei-Dong (Department of Medical Imaging, Jinling Hospital, Clinical School of Medical College, Nanjing University) ;
  • Cao, Jian-Ming (Department of Medical Imaging, Jinling Hospital, Clinical School of Medical College, Nanjing University) ;
  • Xu, Jian (Department of Medical Imaging, Jinling Hospital, Clinical School of Medical College, Nanjing University) ;
  • Chen, Bo (Department of Medical Imaging, Jinling Hospital, Clinical School of Medical College, Nanjing University) ;
  • Yang, Tao (Department of Medical Imaging, Jinling Hospital, Clinical School of Medical College, Nanjing University) ;
  • Xu, Tan-Tan (Department of Medical Imaging, Jinling Hospital, Clinical School of Medical College, Nanjing University) ;
  • Lu, Guang-Ming (Department of Medical Imaging, Jinling Hospital, Clinical School of Medical College, Nanjing University) ;
  • Li, Jun (Department of Oncology, Meishan Hospital Shanhai Meishan Co. Ltd.) ;
  • Huang, Xin-En (Department of Chemotherapy, Jiangsu Cancer Hospital & Research Institute)
  • 발행 : 2012.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objectives: To explore the impact of low- vs conventional-dose chemotherapy via transcatheter arterial chemo-embolization (TACE) on serum fibrosis indicators and treatment efficacy of hepatocellular cancer patients (HCC). Materials and Methods: Patients fulfilling the eligibility criteria were assigned to TACE in Group A (with low-dose chemotherapy) or Group B (conventional-dose chemotherapy). Four serum fibrosis related indicators, hyaluronic acid(HA), human pro-collagen type-III (hPC-III), laminin (LN), and collagen type-IV(IV-C) before TACE were compared with the values 7 days after TACE. The response rate and survival time were also compared between the two groups. Results: Fifty patients with HCC were enrolled in this study, including 25 in Group A and 25 in Group B. No significant differences were detected between the two groups in the four indicators before TACE. After TACE, the value of the four serum indicators increased significantly in Group B. However, no significant differences regarding these four indicators were found in Group A after TACE. Significant differences were demonstrated between the two groups after TACE, but median survival time and 1 or 2 year overall survival rates did not differ (P>0.05). Conclusions: Low-, compared with conventional-dose chemotherapy exerts the same impact on the variation of fibrosis related indicators and has no influence on median survival time and survival rate after TACE in HCC patients.

키워드

참고문헌

  1. Artinyan A, Nelson R, Soriano P, et al (2008). Treatment response to transcatheter arterial embolization and chemoembolization in primary and metastatic tumors of the liver. HPB (Oxford), 10, 396-404. https://doi.org/10.1080/13651820802356564
  2. Britten CD, Gomes AS, Wainberg ZA, et al (2012). Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study. BMC Cancer, 12, 16. https://doi.org/10.1186/1471-2407-12-16
  3. Choi SB, Kim KS, Park YN, et al (2009). The efficacy of hepatic resection after neoadjuvant transarterial chemoembolization (TACE) and radiation therapy in hepatocellular carcinoma greater than 5 cm in size. J Korean Med Sci, 24, 242-7. https://doi.org/10.3346/jkms.2009.24.2.242
  4. Collazos J, Diaz F, Genolla J (1993). Serum concentrations of laminin in cirrhosis of the liver. Gut, 34, 974-6. https://doi.org/10.1136/gut.34.7.974
  5. Gao LL, Huang XE, Zhang Q, et al (2011). 14.A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial. Asian Pac J Cancer Prev, 12, 77-80.
  6. Gong P, Huang XE, Chen CY, et al (2012). Comparison on complications of peripherally inserted central catheters by ultrasound guide or conventional method in cancer patients. Asian Pac J Cancer Prev, 13, 1873-5. https://doi.org/10.7314/APJCP.2012.13.5.1873
  7. Hakamada K, Kimura N, Miura T, et al (2008). Des-gammacarboxy prothrombin as an important prognostic indicator in patients with small hepatocellular carcinoma. World J Gastroenterol, 14, 1370-7. https://doi.org/10.3748/wjg.14.1370
  8. Huang YH, Wu JC, Chau GY, et al (1999). Supportive treatment, resection and transcatheter arterial chemoembolization in resectable hepatocellular carcinoma: an analysis of survival in 419 patients. Eur J Gastroenterol Hepatol, 11, 315-21. https://doi.org/10.1097/00042737-199903000-00017
  9. Huang XE, Li CG, Li Y, et al (2011). Weekly TP regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a phase II trial. Asian Pac J Cancer Prev, 12, 2797-800.
  10. Jiang Y, Huang XE, Yan PW, et al (2010). Validation of Treatment Efficacy of a Computer-assisted Program for Breast Cancer Patients receiving Postoperative Adjuvant Chemotherapy. Asian Pacific J Cancer Prev, 11, 1059-62.
  11. Li CG, Huang XE, Li Y, et al (2011). Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer. Asian Pacific J Cancer Prev, 12, 487-90.
  12. Li CG, Huang XE, Li Y, et al (2011). Clinical observations on safety and efficacy of OxyContin(R) administered by rectal route in treating cancer related pain. Asian Pac J Cancer Prev, 12, 2477-8.
  13. Li CG, Huang XE, Xu L, et al (2012). Clinical application of serum tumor associated material (TAM) from non-small cell lung cancer patients. Asian Pac J Cancer Prev, 13, 301-4. https://doi.org/10.7314/APJCP.2012.13.1.301
  14. Li H, Hu Y, Li N, Zhou Y (2012). Liver fibrosis and five year survival of hepatocellular cancer cases undergoing transcatheter arterial chemo embolization using small doses. Asian Pac J Cancer Prev, 13, 1589-93. https://doi.org/10.7314/APJCP.2012.13.4.1589
  15. Li Y, Yan PW, Huang XE, et al (2011). MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 12, 2405-9.
  16. Liu W, Li SY, Huang XE, et al (2012). Inhibition of tumor growth in vitro by a combination of extracts from rosa roxburghii tratt and fagopyrum cymosum. Asian Pac J Cancer Prev, 13, 2409-14. https://doi.org/10.7314/APJCP.2012.13.5.2409
  17. Malenstein H, Maleux G, Vandecaveye V, et al (2011). A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie, 34, 368-76. https://doi.org/10.1159/000329602
  18. Marelli L, Stigliano R, Triantos C, et al (2007). Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol, 30, 6-25. https://doi.org/10.1007/s00270-006-0062-3
  19. Miraglia R, Pietrosi G, Maruzzelli L, et al (2007). Efficacy of transcatheter embolization/chemoembolization (TAE/ TACE) for the treatment of single hepatocellular carcinoma. World J Gastroenterol, 13, 2952-5.
  20. Paul B, Gamanagatti S, Sreenivas V, et al (2011). Trans-arterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma: experience from a Tertiary Care Centre in India. Indian J Radiol Imaging, 21, 113-20. https://doi.org/10.4103/0971-3026.82294
  21. Pleguezuelo M, Marelli L, Misseri M, et al (2008). TACE versus TAE as therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther, 8, 1623-41. https://doi.org/10.1586/14737140.8.10.1623
  22. Raoul JL, Sangro B. Forner A, et al (2011). Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev, 37, 212-20. https://doi.org/10.1016/j.ctrv.2010.07.006
  23. Resino S, Bellon JM, Asensio C (2010). Can serum hyaluronic acid replace simple non-invasive indexes to predict liver fibrosis in HIV/Hepatitis C coinfected patients? BMC Infect Dis, 10, 244. https://doi.org/10.1186/1471-2334-10-244
  24. Scartozzi M, Baroni GS, Faloppi L, et al (2010). Transarterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis. J Exp Clin Cancer Res, 29, article 164.
  25. Shu J, Li CG, Liu YC, et al (2012).Comparison of Serum Tumor Associated Material (TAM) with Conventional Biomarkers in Cancer Patients. Asian Pac J Cancer Prev, 13, 2399-403. https://doi.org/10.7314/APJCP.2012.13.5.2399
  26. Tam KY, Leung KC, Wang YX, et al (2011). Chemoembolization agents for cancer treatment. Eur J Pharm Sci, 44, 1-10.
  27. Therasse P, Arbuck SG, Eisenhauer EA, et al (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 92, 205-16. https://doi.org/10.1093/jnci/92.3.205
  28. Toyama T, Nitta N, Ohta S, et al (2012). Clinical trial of cisplatin-conjugated gelatin microspheres for patients with hepatocellular carcinoma. Jap J Radiol, 30, 62-8. https://doi.org/10.1007/s11604-011-0010-2
  29. Xu JW, Li CG, Huang XE, et al (2011). Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced gastric cancer cases. Asian Pac J Cancer Prev, 12, 985-7.
  30. Xu HX, Huang XE, Li Y, et al (2011). A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Asian Pac J Cancer Prev, 12, 2233-6.
  31. Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of Endostar(R) combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90.
  32. Xu T, Xu ZC, Zou Q, Yu B, Huang XE (2012). P53 Arg72Pro polymorphism and bladder cancer risk--meta-analysis evidence for a link in Asians but not Caucasians. Asian Pac J Cancer Prev, 13, 2349-54. https://doi.org/10.7314/APJCP.2012.13.5.2349
  33. Yan PW, Huang XE, Jiang Y, et al (2010). A clinical comparison on safety and efficacy of Paclitaxel/Epirubicin (NE) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer. Asian Pac J Cancer Prev, 11, 1115-8.
  34. Yan PW, Huang XE, Yan F, et al (2011). Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinumbased chemotherapy for advanced non small cell lung cancer. Asian Pac J Cancer Prev, 12, 2291-4.
  35. Yu DS, Huang XE, Zhou JN, et al (2012). A Comparative Study on the Value of Anal Preserving Surgery for Aged People with Low Rectal Carcinoma in Jiangsu, China. Asian Pac J Cancer Prev, 13, 2339-40. https://doi.org/10.7314/APJCP.2012.13.5.2339
  36. Zhang LQ, Huang XE, Wang J, (2011). The cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a meta-analysis of 20 populations. Asian Pac J Cancer Prev,12(1):81-5.
  37. Zhang XZ, Huang XE, Xu YL, et al (2012). A Phase II Study on Voriconazole in Treating Chinese Patients with Malignant Hematological Disorder and Invasive Aspergillosis. Asian Pacific J Cancer Prev, 13, 2415-8. https://doi.org/10.7314/APJCP.2012.13.5.2415
  38. Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/ Docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.

피인용 문헌

  1. Application of Lobaplatin in Trans-catheter Arterial Chemoembolization for Primary Hepatic Carcinoma vol.15, pp.2, 2014, https://doi.org/10.7314/APJCP.2014.15.2.647
  2. Safety and Efficacy of Sequential Transcatheter Arterial Chemoembolization and Portal Vein Embolization prior to Major Hepatectomy for Patients with HCC vol.15, pp.2, 2014, https://doi.org/10.7314/APJCP.2014.15.2.703
  3. Lobaplatin Combined Floxuridine/Pirarubicin-based Transcatheter Hepatic Arterial Chemoembolization for Unresectable Primary Hepatocellular Carcinoma vol.15, pp.5, 2014, https://doi.org/10.7314/APJCP.2014.15.5.2057
  4. Drainage Alone or Combined with Anti-tumor Therapy for Treatment of Obstructive Jaundice Caused by Recurrence and Metastasis after Primary Tumor Resection vol.15, pp.6, 2014, https://doi.org/10.7314/APJCP.2014.15.6.2681
  5. Transarterial Therapies for Hepatocellular Carcinoma: a Comprehensive Review with Current Updates and Future Directions vol.17, pp.2, 2016, https://doi.org/10.7314/APJCP.2016.17.2.473